Valvular & structural heart disease
Cardio-Hepatic Syndrome in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair
Authors' conclusion
The CHS is frequently observed in patients undergoing M-TEER and significantly impairs 2-year survival. Successful M-TEER may have beneficial effects on CHS.
Study context
- Population
- Patients undergoing M-TEER for relevant primary or secondary mitral regurgitation (MR) at four European centres, 2008–2019
- Participants
- 1,083 patients
- Exposure
- Ischaemic type I cardio-hepatic syndrome (CHS) and cholestatic type II CHS vs no CHS
- Outcome
- All-cause mortality
- Follow-up
- 2 years
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Prevalence of CHS
Observational data: associations, not effects.
Further findings
Change in hepatic function at follow-up in patients with MR reduction ≤2+ (obtained in 90.7%)
- Median reduction in bilirubin
- 0.2 mg/dl
- Median reduction in alanine aminotransferase
- 0.2 U/L
- Median reduction in gamma-glutamyl transferase
- 21 U/L
- p < 0.01
Original publication
Cardio-Hepatic Syndrome in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair. Eur J Heart Fail. Published 23 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →